KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and safety of etifoxine versus alprazolam in generalized anxiety disorders with somatic symptoms: A randomized, double-blind, comparative study.

Kalmegh Prabhakar, Gopalakrishnan Ganesan, Dhananjay Chaudhari, Nitin Dalaya, Ashish Mohide, Spandan Thaker, Mithun Dutta, Bharati Patil, Asish Mukhopadhyay, Uma Jyothi Neeli, Ashutosh Kumar, Rajagopal Rajendra, Raisa Shaikh, Shruti Saha, Supriya Sonowal, Sapan Behera, Prashant Devkare, Sucheta Pandit, Dipak Patil, Pravin Ghadge, Lalit Lakhwani, Suyog Mehta, Sadhna Joglekar

J Anxiety Disord 119 103147

PMID41763071
PMCID-
DOI10.1016/j.janxdis.2026.103147
发表日期2026-02-28
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

Etifoxine, a non-benzodiazepine anxiolytic, is useful for managing anxiety symptoms. However, its role in managing somatic symptoms in generalized anxiety disorder (GAD) remains unclear. Hence, we aimed to compare the efficacy and safety of Etifoxine with Alprazolam in adults with GAD with somatic symptoms. This phase 3, randomized, double-blind, double-dummy study included 260 patients aged 18-65 years with GAD with somatic symptoms who received either Etifoxine 50 mg TID or Alprazolam 0.5 mg TID (1:1) for 4 weeks. The primary outcome was the change from baseline to day 28 in the Hamilton Anxiety Rating Scale (HAM-A) total score. Secondary efficacy outcomes included changes from baseline to days 7 and 14 in HAM-A total score, changes from baseline to days 7, 14, and 28 in HAM-A psychic and somatic sub-scores, clinical global impression-severity score, and percentage of patients with clinical and patient global impression-improvement scale responses. Our study results indicated that both Etifoxine and Alprazolam demonstrated significant improvements in mean change in HAM-A total scores at day 28 from baseline [mean (SD): -13.5 (4.21) and -13.4 (4.64), respectively; p < 0.0001 for both]. The adjusted mean difference (95% CI) was -0.18 (-1.08, 0.72), indicating non-inferiority of Etifoxine. Changes in secondary efficacy parameters were also comparable between groups. Treatment-emergent AEs were mild and observed in 10% and 7.7% of patients in the Etifoxine and Alprazolam groups, respectively. Etifoxine was non-inferior to Alprazolam in reducing anxiety symptoms in GAD, was well-tolerated, and can be a promising alternative for anxiety management without drug dependence risk.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。